Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-05-12T08:24:47.476Z Has data issue: false hasContentIssue false

Antidepressants in epilepsy

Published online by Cambridge University Press:  01 September 2022

M.M. Gutiérrez Rodríguez*
Affiliation:
HOSPITAL UNIVERSITARIO DE MÓSTOLES, Psychiatry, MÓSTOLES (MADRID), Spain
M.D.L.A. Corral Y Alonso
Affiliation:
HOSPITAL UNIVERSITARIO DE MÓSTOLES, Psychiatry, MÓSTOLES (MADRID), Spain
C. Moreno Menguiano
Affiliation:
HOSPITAL UNIVERSITARIO DE MÓSTOLES, Psychiatry, MÓSTOLES (MADRID), Spain
F. Garcia Sánchez
Affiliation:
HOSPITAL UNIVERSITARIO DE MÓSTOLES, Psychiatry, MÓSTOLES (MADRID), Spain
J.J. Vazquez Vazquez
Affiliation:
Centro de Salud Mental de Móstoles / Hospital Universitario de Móstoles, Psychiatry, Móstoles, Spain
S.M. Bañón González
Affiliation:
Hospital Infanta Sofía, Psiquiatría, Madrid, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Depressive disorders are one of the most frequent psychiatric comorbidity in epilepsy and they have a negative impact on the quality of life. Depression often requires antidepressant treatment. However, it is often left untreated in people with epilepsy, in part due to fear that antidepressants could cause seizures.

Objectives

The goal of this study was to do a review and describe the evidence of the efficacy and safety of pharmacological treatment for depression in epilepsy.

Methods

Review of literature sources were obtained through electronic search in PubMed database with special focus in papers published in the last 5 years.

Results

The existing evidence of the effectiveness of antidepressants in treating depressive symptoms associated with epilepsy is still limited and response rate was highly variable. It is essential first to optimize seizure control and minimize unwanted antiepileptic drug-related side effects. As the first line of treatment you should consider the use of SSRI or IRSN. The improvement in depressive symptoms ranged from 25% to 82% according to the different studies and depending on the antidepressant administered. A review of the literature indicates that the risk of antidepressant-associated seizures is low although some antidepressants such as amoxapine or bupropion are not recommended.

Conclusions

There are few comparative data to support the choice of antidepressant drug or drug class in terms of efficacy or safety for the treatment of people with epilepsy and depression. It would be important to design controlled trials of antidepressants in large cohorts of participants with epilepsy and clinically significant depression.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.